AngioDynamics Inc. Annual stock financials by MarketWatch. View the latest ANGO financial statements, income statements and financial ratios.

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...

Total Revenue: $72 million, representing a growth of over 9% year over year. MedTech Revenue: $31.3 million, a 22.2% increase. Med Device Revenue: $40.7 million, a 0.9% increase. Gross Margin: 54%, an ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...

Another mixed quarter in Q3 FY'22 for AngioDynamics, despite strengths in its international markets. Management revised guidance higher, but this may widen the operating loss as well, in my view.

Well, good morning, everyone. Thank you for joining us. I'm Danielle Antalffy, the U.S. MedTech analyst here at UBS. And happy to kick off our Annual Healthcare Conference with the AngioDynamics team.